# Marc Foidart

> Marc Foidart is a Series B investor at Epimède SA backing Medical and Health Care. See 2 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Epimède SA](https://shizune.co/investors/profile/epim%C3%A8de-sa)
- Total investments: 2
- Last investment: Oct 2018
- Lead investor: 100%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/marc-foidart-55b32412/

Marc Foidart is a Series B investor at Epimède SA focused on Medical and Health Care. Marc Foidart - Investment Manager @ Epimède SA

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 2 | 100% |
| Health Care | 2 | 100% |
| Biotechnology | 1 | 50% |
| Pharmaceutical | 1 | 50% |
| Health Diagnostics | 1 | 50% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 1 | 50% |
| Funding Round | 1 | 50% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| France | 1 | 50% |
| The Netherlands | 1 | 50% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Magnisense | Magnisense conçoit, développe et commercialise des tests de diagnostic d'urgence pour les maladies cardio-vasculaires à partir de sa technologie MIAtek® et de son instrument de diagnostic propriétaires | $5.5M |  | Oct 26, 2018 |  |
| Ncardia | Ncardia is an Operator of a biotechnology company intended to expedite drug discovery and development process.The company uses hiPSC stem cell technology to develop predictive human cellular assay systems for safety and efficacy testing of drug candidates as well as enhance cardiovascular and neural drug screening, enabling researchers to bringpredictive human disease biology and accelerate drug discovery. | $11.5M | Series B | Nov 17, 2017 |  |

2 of 2 investments shown.

## Co-investors
- [Concorde Capital](https://shizune.co/investors/profile/concorde-capital) — VC Fund, 1 deal together
- [InnovationQuarter](https://shizune.co/investors/profile/innovation-quarter) — VC Fund, 1 deal together
- [Minv](https://shizune.co/investors/profile/minv) — VC Fund, 1 deal together
- [Provestis](https://shizune.co/investors/profile/provestis) — VC Fund, 1 deal together
- [Sambrinvest](https://shizune.co/investors/profile/sambr-invest) — VC Fund, 1 deal together
- [SFPI-FPIM](https://shizune.co/investors/profile/sfpi-fpim) — VC Fund, 1 deal together

## About Epimède SA

VC Fund

Epimède SA

1 contacts available at Epimède SA.

| Name | Title | Profile |
| --- | --- | --- |
| Marc Foidart | Investment Manager | https://shizune.co/investors/profile/marc-foidart |

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Marc Foidart invest in?

Marc Foidart invests primarily in Medical, Health Care and Biotechnology startups, most often at Series B and Funding Round stage. Most of the 2 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Marc Foidart last invest?

The most recent investment recorded for Marc Foidart closed in Oct 2018. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co